Neoplasms

All Conditions

Nervous System Diseases

Symptoms and General Pathology

Carcinoma

Sarcopenia

Head and Neck Neoplasms

Muscular Atrophy

Atrophy

Neuromuscular Manifestations

Neurologic Manifestations

Pathological Conditions, Anatomical

Patient diagnosed with head \& neck carcinoma at diagnosis

evaluation of sarcopenia by CT san at the C3 vertebrae

sarcopenia assessment

Magali BALAVOINE

Jonas DUBU

Katell LE DÛ, MD

Amandine RUFFIER, MD

LE DU Katell, MD

Sarcopenia is defined by the reduction in skeletal muscle mass and physical performance. It results in a decrease in muscle strength, overall physical activity, walking and the development of balance disorders and falls. It is one of the natural consequences of aging and contributes to frailty and the appearance of geriatric syndrome (s) (Chandapasirt et al, 2015; Cruz-Jentoft et al, 2010).

Its prevalence in patients with Head \& Neck cancer is 39% (Hua et al, 2020) and is associated with an increase in postoperative complications (Achim et al, 2017; Bril et al, 2019), with greater toxicity of chemotherapy. (Wendrich et al, 2017) and reduced overall survival (Hua et al, 2020).

It is measured by CT scan (assessment of muscle volume with respect to L3 using IMAGE J software) (Teigen et al, 2018) and by clinical tests (performance tests) (Swartz et al, 2016, Cruz-Jentoft et al, 2010).

Several studies have shown a possible assessment of sarcopenia by measuring skeletal muscle mass with regard to C3 (Ufuk et al, 2019; Swartz et al, 2016).

This trial aims to evaluate the prevalence of sarcopenia in head and neck cancer evaluated by CT at C3.

Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head & Neck Cancer

Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head & Neck Carcinoma

Number of patients with sarcopenia at diagnosis and during treatments

Number of patients presenting an hypoalbuminemia.

Number of patients with a BMI \<18 and with a prescription for nutritional complements.

Number of patients having the complete planned treatment

Number of patients with a complete response on the end-of-treatment evaluation scanner according to the RECIST or PERCIST criteria in the numerator out of the total number of patients in the denominator

Number of hospitalizations per patient for treatment-related complications

Weprom

Neoplasm Metastasis

Katell LE DU, MD

Cancer is one of the leading causes of death in the world after cardiovascular disease (8.7 million deaths in 2015 for 17.5 million cases) 1. Despite a great deal of progress in disease detection and treatment, the incidence of cancer is steadily increasing (+ 33% in 2015) and particularly in certain locations (pancreas, lungs, brain and stomach), including risk factors are not always identified.

Advanced stage cancer (= metastatic) is most often incurable with the exception of germ cell tumors. Palliative care is then most often offered. Palliative care favors the patient's quality of life as a whole (medical, physical, psychological and social).

The symptoms most often reported by patients are: pain, fatigue, decreased appetite, nausea, and are directly related to phenomena such as cachexia, loss of autonomy and deterioration of psychological state, resulting in decreased overall survival. Chemotherapies and targeted therapies (immunotherapy, hormonal therapy, participation in a clinical trial) can provide a benefit in quality of life and survival only in the early phase (little benefit in the terminal phase).

Other prognostic factors can impact the quality of life and overall survival in these situations: sarcopenia and disorders of nutritional status (obesity, undernutrition).

The study of sarcopenia by CT scan of patients in a palliative situation is still too scarce. Sarcopenia is an often underestimated event and is associated with older age, co-morbidities, increased infectious complications, and early mortality.

The study of the prevalence of sarcopenia by CT scan would confirm its prognostic impact in a palliative situation.

Assessment of the Prevalence of Sarcopenia in Early Palliative Cancer Patients

Number of patients with sarcopenia in the numerator out of the total number of patients included in the study in the denominator

Number of patients with nutritional disorders at inclusion in numerator out of the number of patients followed in denominator

Time between the inclusion date and the date of death regardless of the cause or the date of the latest news if the patient is censored

Time between the inclusion date and the date of the first examination showing Time disease progression or the date of death if the patient is deceased or the date of the latest news if the patient is censored

Time between the date of inclusion and the date of the first event identified or the date of death if the patient is deceased or the date of the latest news if the patient is censored

Calculation of PRONOPALL score (high score corresponds to a worse situation)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head & Neck Cancer	NCT04804852	Sarcopenia Cancer of Head ... CT Scan	sarcopenia asse...	18 Years -	Weprom
Assessment of the Prevalence of Sarcopenia in Early Palliative Cancer Patients	NCT04714203	Metastatic Canc...	sarcopenia asse...	18 Years -	Weprom
Assessment of the Prevalence of Sarcopenia in Early Palliative Cancer Patients	NCT04714203	Metastatic Canc...	sarcopenia asse...	18 Years -	Weprom

Spots Global Cancer Trial Database for sarcopenia assessment